Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables

Clinical and Experimental Metastasis

Volumn 22, Issue 6, 2005, Pages 495-502

  Decock, J ^a   Hendrickx, W ^a   Wildiers, H ^a   Christiaens, M R ^a   Neven, P ^a   Drijkoningen, M ^a   Paridaens, R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Axillary lymph node status; Breast cancer; Gelatinases; Her2 neu expression; Matrix metalloproteinases; Plasma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE; GELATINASE A; GELATINASE B; HORMONE RECEPTOR;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; HIGH RISK POPULATION; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 28644445180     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-005-3992-2     Document Type: Article

References (31)

1. MP Coleman G Gatta A Verdecchia 2003 EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century Ann Oncol 14 Suppl 5 v128 v149
2. WL [tmp] McGuire GM Clark 1992 Prognostic factors and treatment decisions in axillary-node-negative breast cancer N Engl J Med 326 26 1756 61
3. M Egeblad Z Werb 2002 New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 3 161 74
4. MA Lafleur MM Handsley DR Edwards 2003 Metalloproteinases and their inhibitors in angiogenesis Expert Rev Mol Med 2003 1 39
5. G La Rocca I Pucci-Minafra A Marrazzo 2004 Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera Br J Cancer 90 7 1414 21
6. A Talvensaari-Mattila P Paakko M Hoyhtya 1998 Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma Cancer 83 6 1153 62
7. A Scorilas A Karameris N Arnogiannaki 2001 Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients Br J Cancer 84 11 1488 96
8. A Talvensaari-Mattila P Paakko T Turpeenniemi-Hujanen 1999 MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma Breast Cancer Res Treat 58 3 287 93
9. A Talvensaari-Mattila P Paakko G Blanco-Sequeiros T Turpeenniemi-Hujanen 2001 Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy Breast Cancer Res Treat 65 1 55 61
10. A Talvensaari-Mattila P Paakko T Turpeenniemi-Hujanen 2003 Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma Br J Cancer 89 7 1270 5
11. SM Sheen-Chen HS Chen HL Eng 2001 Serum levels of matrix metalloproteinase 2 in patients with breast cancer Cancer Lett 173 1 79 82
12. S Zucker RM Lysik MH Zarrabi U Moll 1993 M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer Cancer Res 53 1 140 6
13. S Zucker M Hymowitz C Conner 1999 Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications Ann N Y Acad Sci 878 212 27
14. S Leppa T Saarto L Vehmanen 2004 A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma Clin Cancer Res 10 3 1057 63
15. SM Ranuncolo E Armanasco C Cresta 2003 Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients Int J Cancer 106 5 745 51
16. KM Keller JM Keller K Kuhn 1986 The C-terminus of type I collagen is a major binding site for heparin Biochim Biophys Acta 882 1 1 5
17. GS Makowski ML Ramsby 2003 Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma Anal Biochem 322 2 283 6
18. UM Wallon CM Overall 1997 The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components J Biol Chem 272 11 7473 81
19. K Jung M Lein C Laube R Lichtinghagen 2001 Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood Clin Chim Acta 314 1-2 241 4
20. R Hanemaaijer JH Verheijen TM Maguire 2000 Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors Int J Cancer 86 2 204 7
21. RB Dickson ME Lippman 1995 Growth factors in breast cancer Endocr Rev 16 5 559 89
22. G Konecny M Untch J Arboleda 2001 Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer Clin Cancer Res 7 8 2448 57
23. F Bertucci N Borie C Ginestier 2004 Identification and validation of an ERBB2 gene expression signature in breast cancers Oncogene 23 14 2564 75
24. D Giunciuglio M Culty G Fassina 1995 Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes Int J Cancer 63 6 815 22
25. P O'Charoenrat P Rhys-Evans WJ Court 1999 Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands Clin Exp Metastasis 17 7 631 9
26. A Roetger A Merschjann T Dittmar 1998 Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model Am J Pathol 153 6 1797 806
27. M Tan J Yao D Yu 1997 Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities Cancer Res 57 6 1199 205
28. FJ Xu S Stack C Boyer 1997 Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis Clin Cancer Res 3 9 1629 34
29. D Yu SS Wang KM Dulski 1994 c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties Cancer Res 54 12 3260 6
30. JM Pellikainen KM Ropponen VV Kataja 2004 Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis Clin Cancer Res 10 22 7621 8
31. J Westermarck VM Kahari 1999 Regulation of matrix metalloproteinase expression in tumor invasion FASEB J 13 8 781 92